Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Published:2005-06 Issue:6 Volume:129 Page:763-770
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kyriakou Charalampia,Thomson Kirsty,D'Sa Shirley,Flory Angela,Hanslip Judith,Goldstone Anthony H.,Yong Kwee L.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2005.05521.x/fullpdf

Reference43 articles.

1. The Treatment of Multiple Myeloma

2. Thalidomide and dexamethasone for resistant multiple myeloma

3. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

4. High-dose therapy and innovative approaches to treatment of multiple myeloma

5. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma;Targeted Oncology;2022-06-30

2. Oral Therapies for Multiple Myeloma;Oncology & Haematology;2022

3. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients;Journal of Clinical Medicine;2020-06-06

4. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study;Clinical Lymphoma Myeloma and Leukemia;2020-02

5. Optimizing therapy in bortezomib-exposed patients with multiple myeloma;Expert Review of Hematology;2018-05-28